Outcomes and Safety Profile of Repeated Progressive Site-Directed Therapy for Patients With Oligometastatic Castration-Resistant Prostate Cancer.
0/5 보강
APA
Yasuda Y, Yoshida S, et al. (2026). Outcomes and Safety Profile of Repeated Progressive Site-Directed Therapy for Patients With Oligometastatic Castration-Resistant Prostate Cancer.. International journal of urology : official journal of the Japanese Urological Association, 33(1), e70253. https://doi.org/10.1111/iju.70253
MLA
Yasuda Y, et al.. "Outcomes and Safety Profile of Repeated Progressive Site-Directed Therapy for Patients With Oligometastatic Castration-Resistant Prostate Cancer.." International journal of urology : official journal of the Japanese Urological Association, vol. 33, no. 1, 2026, pp. e70253.
PMID
41035296 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Real-world insights from comprehensive genomic profiling in patients with metastatic castration-resistant prostate cancer.
- Bayesian Reanalysis of Adjuvant Nivolumab in Japanese Patients With High-Risk Muscle-Invasive Urothelial Carcinoma.
- Real-World Comparison of Triplet Versus Doublet Therapy in Japanese Patients With High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Propensity-Weighted Analysis From the YUSHIMA Registry and Exploratory Bayesian Evidence Synthesis.
- Successful Rechallenge of Trastuzumab Deruxtecan Following Early Detection of ILD in a Patient with Non-small Cell Lung Carcinoma Harboring HER2 Exon 20 Insertion.
- Restricted mean survival time comparison of olaparib plus abiraterone versus talazoparib plus enzalutamide in first-line metastatic castration-resistant prostate cancer: indirect analyses of propel and talapro-2.